The tumor microenvironment (TME) plays a crucial role in cancer progression and immune
evasion, partially mediated by the activity of the TME-derived exosomes. These extracellular …

Abstract Treatment options for relapsed/refractory (R/R) diffuse large B-cell lymphoma
(DLBCL) are limited, with no standard of care; prognosis is poor, with 4-to 6-month median …

Background: Common variable immunodeficiency disorder (CVID) is one of the most
frequent inborn errors of immunity, increased occurrence of malignancies, particularly …

Objective The systemic immune-inflammation index (SII) based on neutrophil, platelet and
lymphocyte counts, is a prognostic biomarker in some solid cancers. However, the …

Background/Aims: Diffuse large B-cell lymphoma (DLBCL), the most common subtype of
non-Hodgkin lymphoma, has significant prognostic heterogeneity. This study aimed to …

In the last decade, advancements in immunotherapy knowledge have highlighted CTLA-4,
PD-1, LAG-3, TIM-3, and TIGIT, decisive immune checkpoints exhibiting within the tumor …

Background: It has been verified that deficiency of Qi, a fundamental substance supporting
daily activities according to the Traditional Chinese Medicine theory, is an important …

Lymphocytes play crucial roles in tumor surveillance in diffuse large B-cell lymphoma
(DLBCL). Neutrophil-to-lymphocyte ratio (NLR), a biomarker for systematic inflammation …

Abstract Background Anti‐CD20 monoclonals (MoAbs) are used in a variety of autoimmune
disorders. The aim is to eliminate memory B cells sustaining the tissue damage and the …

Peripheral blood gene expression intensity-based methods for distinguishing healthy
individuals from cancer patients are limited by sensitivity to batch effects and data …